Oramed Pharmaceuticals (NASDAQ:ORMP) Lowered to Sell Rating by StockNews.com

StockNews.com downgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a report released on Saturday morning.

Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Stock Performance

ORMP stock opened at $2.44 on Friday. The stock’s 50 day simple moving average is $2.38 and its 200 day simple moving average is $2.41. The company has a market cap of $98.36 million, a P/E ratio of 22.18 and a beta of 1.70. Oramed Pharmaceuticals has a fifty-two week low of $2.00 and a fifty-two week high of $3.67.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP raised its stake in shares of Oramed Pharmaceuticals by 52.1% in the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after buying an additional 108,700 shares in the last quarter. XTX Topco Ltd purchased a new stake in Oramed Pharmaceuticals in the 2nd quarter valued at $40,000. Murchinson Ltd. lifted its stake in Oramed Pharmaceuticals by 23.2% during the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock valued at $4,369,000 after acquiring an additional 320,495 shares in the last quarter. Finally, BML Capital Management LLC boosted its holdings in Oramed Pharmaceuticals by 62.1% during the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock worth $5,334,000 after acquiring an additional 837,153 shares during the last quarter. Institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.